Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,418 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Iron, Diabetes, Nonalcoholic Fatty Liver
Interventions: Blood Donation, Sham Blood Donation; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: ADHD, Growth
Interventions: behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement; Behavioral · Drug · Other + 1 more
Lead sponsor: Florida International University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COVID-19, Coronavirus, SARS-CoV-2
Interventions: pathogen reduced SARS-CoV-2 convalescent plasma, Placebo; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 974 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 26
States / cities: Little Rock, Arkansas • La Jolla, California • Aurora, Colorado + 22 more

Conditions: Cardiac Arrest From Trauma
Interventions: Emergency preservation and resuscitation, Standard resuscitation; Combination Product · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure
Interventions: Furosemide-Q12 hour bolus, Furosemide-Continuous Infusion, Furosemide-Low Intensification, Furosemide-High Intensification; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 8
States / cities: Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 5 more

Conditions: Postherpetic Neuralgia, Pain
Interventions: NGX-1998, Placebo Liquid; Drug
Lead sponsor: NeurogesX; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 35
States / cities: Huntsville, Alabama • Tucson, Arizona • Irvine, California + 32 more

Conditions: Hydrocephalus
Interventions: Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC), Ventriculoperitoneal Shunt; Procedure · Device
Lead sponsor: University of Utah; Other
Eligibility: 1 Day to 104 Weeks
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more

Conditions: Acute Spinal Cord Injury, Acute Spinal Paralysis, Spinal Cord Injuries, SPINAL Fracture
Interventions: SCPP Management => 65 mmHg; Procedure
Lead sponsor: University of British Columbia; Other
Eligibility: 17 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 4
States / cities: San Francisco, California • Omaha, Nebraska • Albuquerque, New Mexico + 1 more

Conditions: Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies
Interventions: IGIV-C, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, SARS-CoV2
Interventions: SAB-185, Normal saline; Biological · Other
Lead sponsor: SAb Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 3
States / cities: Wichita, Kansas • Syracuse, New York • San Antonio, Texas

Conditions: Hidradenitis Suppurativa
Interventions: Cryoinsufflation, Deroofing; Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Gastrointestinal Disease, Colorectal Cancer
Interventions: Pure-Vu System; Device
Lead sponsor: Motus GI Medical Technologies Ltd; Industry
Eligibility: 22 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: AZD2624; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Traumatic Brain Injury
Interventions: Ovidrel, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Postoperative Complication
Interventions: Goal-directed Therapy group; Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Orange, California

Conditions: Sepsis, Severe Sepsis, Septic Shock
Interventions: Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC); Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 1,351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more

Conditions: Hyperkalemia
Interventions: Patiromer Powder for Oral Suspension [Veltassa], Placebo; Drug
Lead sponsor: Comprehensive Research Associates; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 19
States / cities: Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more

Conditions: Myelomeningocele
Interventions: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix, Untreated contemporaneous cohort; Biological · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 19 Weeks to 25 Weeks
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Current Vaper, Healthy Subject
Interventions: Behavioral Intervention, Questionnaire Administration; Behavioral · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Generalized Tonic Clonic Seizures
Interventions: Pregabalin Dose Level 1, Pregabalin Dose Level 2, Placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 12
States / cities: Loxahatchee Groves, Florida • Orlando, Florida • Port Charlotte, Florida + 6 more

Conditions: Osteoarthritis of the Knee
Interventions: TLC599, DSP; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Miami, Florida • Charleston, South Carolina + 2 more

Conditions: Mature B-Cell Lymphoma
Interventions: COPAD, COP, COPD M3, CYM, COP, COPADM8, CYVE; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 2
States / cities: San Diego, California • Memphis, Tennessee

Conditions: Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
Interventions: Cryoablation Therapy, Nivolumab, Ipilimumab; Procedure · Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 1 Year to 39 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Overweight, Autism Spectrum Disorder
Interventions: Metformin, Placebo; Drug
Lead sponsor: Holland Bloorview Kids Rehabilitation Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania • Nashville, Tennessee

Search by objective public record fields.

Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

Emergency Preservation and Resuscitation (EPR) for Cardiac Arrest From Trauma

Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)

Study of NGX-1998 for the Treatment of Postherpetic Neuralgia

HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study

The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

Safety and Treatment of Cryoinsufflation in Treatment of Hidradenitis Suppurativa

Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

hCG Treatment for Rehabilitation From a TBI

Goal Directed Fluid Management Based on Non-invasive Monitoring

Protocolized Care for Early Septic Shock

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial

Consumer Assessment of Tobacco Flavor and Odor

A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

Mature B-Cell Lymphoma And Leukemia Study III

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)